IFNG and acute myeloid leukemia: We also found that gilteritinib could significantly increase the secretion of IL-2 and IFN-γ by FLT3scFv/NKG2D-CAR T cells stimulated by AML cell lines (MOLM-13 and MV4-11) (Fig. 2D).